L-Ornithine L-Aspartate Therapy for Hepatic Encephalopathy

Administration and Efficacy

• The recommended dose for intravenous L-ornithine L-aspartate (LOLA) is 30 g/day for patients with hepatic encephalopathy, as suggested by the Clinical and Molecular Hepatology guidelines 1, 2
• Intravenous administration of LOLA may be more effective than oral administration in reducing blood ammonia levels and improving symptoms of hepatic encephalopathy, according to the Journal of Hepatology 3
• Oral supplementation with LOLA may decrease the time of numeric connection test (NCT-A) and plasma ammonia concentrations, as reported by the Clinical and Molecular Hepatology guidelines 1

Special Populations

• In patients with decompensated cirrhosis, LOLA has been used safely as part of the treatment for hepatic encephalopathy, as suggested by the Clinical and Molecular Hepatology and Journal of Hepatology guidelines 1, 3
• For patients with West-Haven grade 1-2 hepatic encephalopathy, intravenous LOLA may be more effective than placebo, according to the Clinical and Molecular Hepatology guidelines 1

Safety and Precautions

• There are no specific contraindications documented in the reviewed clinical guidelines, as reported by the Clinical and Molecular Hepatology, Hepatology, and Journal of Hepatology guidelines 1, 3, 4
• LOLA has a better safety profile compared to antibiotics such as neomycin and metronidazole, which are not recommended for the management of hepatic encephalopathy due to their side effects, as suggested by the Clinical and Molecular Hepatology guidelines 1

Role of L-Ornithine L-Aspartate in Hepatic Encephalopathy Treatment

Mechanism of Action and Clinical Indications

• L-ornithine L-aspartate works by lowering blood ammonia through stimulation of urea synthesis in periportal hepatocytes 5

Clinical Evidence and Guidelines

• The European Association for the Study of the Liver recommends intravenous L-ornithine L-aspartate as an alternative or additional ammonia-lowering agent for patients with hepatic encephalopathy who are nonresponsive to conventional therapy with lactulose and rifaximin, with a GRADE I, B, 2 recommendation 6, 5
• Intravenous administration of L-ornithine L-aspartate has been shown to improve psychometric testing and postprandial venous ammonia levels in patients with persistent hepatic encephalopathy 6, 5
• L-ornithine L-aspartate occupies a third-line position in hepatic encephalopathy management, after lactulose and rifaximin 6, 7

Safety and Efficacy

• Oral L-ornithine L-aspartate is ineffective and should not be used, according to the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 6, 7
• Intravenous L-ornithine L-aspartate has a favorable tolerability profile, with no specific contraindications documented in major guidelines 6, 7

L-Ornithine L-Aspartate for Hepatic Encephalopathy Management

Introduction to L-Ornithine L-Aspartate

• The American Association for the Study of Liver Diseases recommends intravenous L-ornithine L-aspartate at 30 g/day as an effective adjunctive therapy for hepatic encephalopathy in cirrhotic patients, particularly for West-Haven grade 1-2 encephalopathy, where it accelerates recovery when combined with lactulose and reduces ammonia levels more effectively than placebo 8, 9

Mechanism and Rationale

• L-Ornithine L-Aspartate works by providing ornithine and aspartate as substrates for ammonia metabolism, facilitating conversion to urea in periportal hepatocytes and glutamine production, thereby lowering plasma ammonia concentrations that drive hepatic encephalopathy 8

Clinical Evidence and Positioning

• The Clinical and Molecular Hepatology guidelines recommend 30 g/day intravenous L-ornithine L-aspartate as the guideline-recommended dose for hepatic encephalopathy treatment 8, 9, 10
• For West-Haven grade 1-2 hepatic encephalopathy, intravenous L-ornithine L-aspartate reduces Number Connection Test-A times and plasma ammonia concentrations more effectively than placebo 8, 9
• When combined with lactulose, intravenous L-ornithine L-aspartate (30 g/day) produces lower hepatic encephalopathy grades within 1-4 days and faster symptom recovery compared to lactulose alone 8, 9

Safety Profile

• L-Ornithine L-aspartate demonstrates a better safety profile compared to older antibiotics like neomycin and metronidazole, which are not recommended for hepatic encephalopathy management 8, 10

Practical Implementation Algorithm

• The Journal of Hepatology recommends initiating lactulose (titrate to 2-3 soft stools daily) as first-line treatment for hepatic encephalopathy 8, 11, 12
• Rifaximin 550 mg twice daily can be added as second-line treatment if there is an inadequate response to lactulose 8, 10
• Intravenous L-ornithine L-aspartate 30 g/day can be considered as third-line treatment for persistent hepatic encephalopathy despite lactulose/rifaximin, or for West-Haven grade 1-2 encephalopathy requiring faster recovery 8, 9

L-Ornithine L-Aspartate Therapy for Hepatic Encephalopathy

Introduction to L-Ornithine L-Aspartate

• The Critical Care Medicine 2023 guideline suggests the use of L-Ornithine L-Aspartate (LOLA) in patients with Acute-on-Chronic Liver Failure (ACLF) and overt hepatic encephalopathy, with a recommendation based on low-quality evidence 13

Position of LOLA in Therapy Algorithm

• The European Association for the Study of the Liver recommends LOLA intravenously as an alternative or additional ammonia-lowering agent for patients with hepatic encephalopathy who are non-responsive to conventional therapy with lactulose and rifaximin, although the quality of evidence is considered low 13

Evidence from Clinical Trials

• A meta-analysis of 29 clinical trials with 1891 participants showed that LOLA has a beneficial effect on hepatic encephalopathy compared to placebo or no intervention, with a relative risk of 0.70 (95% CI 0.59-0.83), although the quality of evidence was rated as very low 13

Specific Findings from Research

• In a subgroup analysis, LOLA was effective versus placebo in patients with overt hepatic encephalopathy grade I or II (RR 1.87; 95% CI 1.30-2.68; P = 0.0007) 13
• Administration of LOLA intravenously may be more effective than oral administration in reducing blood ammonia levels and improving symptoms of hepatic encephalopathy, as suggested by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver guidelines 13

Animal Model Evidence

• In an animal model of Acute Liver Failure, L-ornithine-L-aspartate has been shown to be beneficial in rats with liver devascularization 14, 15

L‑Ornithine L‑Aspartate (LOLA) in Hepatic Encephalopathy

Mechanism of Action

• LOLA is a stable salt of the endogenous amino acids ornithine and aspartate that provides substrate for two ammonia‑detoxifying pathways: urea synthesis in peri‑portal hepatocytes and glutamine production via glutamine synthetase, thereby lowering plasma ammonia that drives hepatic encephalopathy. 16
• The dual mechanism (urea cycle + glutamine synthesis) distinguishes LOLA from lactulose (luminal ammonia trapping) and rifaximin (microbial ammonia reduction). 16

Dosing and Administration

• Guideline‑recommended regimen: 30 g per day administered as a continuous intravenous infusion over 24 h for 5 days, used in combination with lactulose and rifaximin. 16

Clinical Efficacy

Mild‑to‑moderate Overt HE (West‑Haven Grade 1‑2)

• IV LOLA reduces psychometric test (Number Connection Test‑A) times and plasma ammonia concentrations more effectively than placebo in patients with grade 1‑2 hepatic encephalopathy. 16
• When added to lactulose, 30 g/day IV LOLA yields lower HE grades within 1‑4 days (odds ratio 2.06‑3.04) and faster symptom recovery (mean 1.92 days vs 2.50 days; P = 0.002) compared with lactulose alone. 16

Safety and Guideline Endorsement

• LOLA shows a more favorable safety profile than older antibiotics such as neomycin (which can cause malabsorption, nephro‑ and ototoxicity) and metronidazole (which can cause peripheral neuropathy); these agents are not recommended for hepatic encephalopathy management. 16
• Both the Korean Association for the Study of the Liver (2020) and the European Association for the Study of the Liver endorse the use of IV LOLA as an adjunct ammonia‑lowering therapy; the recommendation is graded as moderate quality (GRADE I, B, 2). 16